NASDAQ:RNLX Renalytix (RNLX) Stock Price, News & Analysis → Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (From Colonial Metals) (Ad) Free RNLX Stock Alerts $0.63 0.00 (0.00%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$0.59▼$0.6750-Day Range$0.62▼$1.4752-Week Range$0.24▼$4.04Volume618,408 shsAverage Volume164,861 shsMarket Capitalization$38.85 millionP/E RatioN/ADividend YieldN/APrice Target$5.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Renalytix alerts: Email Address Renalytix MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside695.2% Upside$5.00 Price TargetShort InterestHealthy1.09% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.31 out of 5 starsComputer And Technology Sector388th out of 590 stocksMedical Laboratories Industry12th out of 19 stocks 3.5 Analyst's Opinion Consensus RatingRenalytix has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageRenalytix has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.09% of the outstanding shares of Renalytix have been sold short.Short Interest Ratio / Days to CoverRenalytix has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Renalytix has recently decreased by 15.28%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldRenalytix does not currently pay a dividend.Dividend GrowthRenalytix does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RNLX. Previous Next 2.2 News and Social Media Coverage News SentimentRenalytix has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Computer and Technology companies.News Coverage This WeekMarketBeat has tracked 1 news article for Renalytix this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for RNLX on MarketBeat in the last 30 days. This is a decrease of -87% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Renalytix insiders have not sold or bought any company stock.Percentage Held by Insiders18.30% of the stock of Renalytix is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 9.92% of the stock of Renalytix is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Renalytix is -1.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Renalytix is -1.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRenalytix has a P/B Ratio of 4.19. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Banyan Hill PublishingForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)Watch my video for all of the details About Renalytix Stock (NASDAQ:RNLX)Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix Plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; and Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is based in New York, New York.Read More RNLX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RNLX Stock News HeadlinesApril 17, 2024 | msn.comRenalytix files to sell 19.99M ordinary shares for holdersApril 9, 2024 | marketwatch.comRenalytix Sells Stock to Raise Up to $4 MlnApril 27, 2024 | Prosper Trading Academy (Ad)These AI trades triggered this morning (545% return)If you think a market crash is possible in 2024, I don't know why you're not using this yet.April 8, 2024 | globenewswire.comRenalytix Announces Financing with Expected Size of up to $4 MillionMarch 25, 2024 | investorplace.com3 Ridiculously Enticing Stocks to Buy for Under a BuckMarch 14, 2024 | stockhouse.comKidneyIntelX(TM) included in Final KDIGO 2024 Clinical Guideline for Chronic Kidney Disease (CKD)March 14, 2024 | globenewswire.comKidneyIntelX™ included in Final KDIGO 2024 Clinical Guideline for Chronic Kidney Disease (CKD)March 12, 2024 | msn.comGoogle restricts election queries by AI model Gemini - reportApril 27, 2024 | Prosper Trading Academy (Ad)These AI trades triggered this morning (545% return)If you think a market crash is possible in 2024, I don't know why you're not using this yet.March 12, 2024 | msn.comNew Zealand air-safety authorities to seize flight recorders for Latam 787March 5, 2024 | markets.businessinsider.comBuy Rating Affirmed for Renalytix AI Amidst Potential Acquisition and Strong Market ProspectsMarch 4, 2024 | msn.comWhy Is AI-Powered Diagnostic Firm Renalytix Stock Soaring On Monday?March 4, 2024 | msn.comRenalytix approached by potential buyer, stock rallies 28%February 29, 2024 | msn.comWhy Is Kidney-Disease Diagnostic Focused Renalytix Stock Trading Higher Today?February 24, 2024 | msn.comRenalytix Plc - Depositary Receipt () (RNLX) Price Target Increased by 21.81% to 5.97February 15, 2024 | finance.yahoo.comRenalytix Reports Financial Results for Second Quarter of Fiscal Year 2024February 15, 2024 | globenewswire.comRenalytix Reports Financial Results for Second Quarter of Fiscal Year 2024February 13, 2024 | msn.comU.S. shares mixed at close of trade; Dow Jones Industrial Average up 0.33%February 12, 2024 | msn.comRenalytix surges after Medicare draft decision on lead productFebruary 11, 2024 | msn.comWall Street Set to Open Modestly Higher as S&P Hovers Just Above 5,000February 10, 2024 | markets.businessinsider.comRenalytix AI Anticipates Medicare Coverage MilestoneFebruary 9, 2024 | markets.businessinsider.comStrong Buy for Renalytix AI: Undervalued Stock with Promising Market Prospects and Strategic Growth CatalystsFebruary 9, 2024 | globenewswire.comRenalytix to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools ConferenceJanuary 10, 2024 | finance.yahoo.comNew published data demonstrates KidneyIntelX™ has broad implications for winning war on chronic kidney diseaseDecember 31, 2023 | markets.businessinsider.comBTIG Keeps Their Buy Rating on Renalytix AI (RNLX)December 30, 2023 | benzinga.comRenalytix Stock (NASDAQ:RNLX) Dividends: History, Yield and DatesNovember 14, 2023 | finanznachrichten.deRenalytix plc: Renalytix Reports Financial Results for First Quarter of Fiscal Year 2024See More Headlines Receive RNLX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Renalytix and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/14/2024Today4/27/2024Next Earnings (Estimated)6/14/2024Fiscal Year End6/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorComputer and Technology Industry Medical laboratories Sub-IndustryN/A Current SymbolNASDAQ:RNLX CUSIPN/A CIK1811115 Webwww.renalytixai.com Phone44-20-3139-2910FaxN/AEmployees102Year FoundedN/APrice Target and Rating Average Stock Price Target$5.00 High Stock Price Target$5.00 Low Stock Price Target$5.00 Potential Upside/Downside+695.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.45) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-45,610,000.00 Net Margins-1,736.47% Pretax Margin-1,736.18% Return on Equity-1,008.88% Return on Assets-155.62% Debt Debt-to-Equity RatioN/A Current Ratio0.59 Quick Ratio0.59 Sales & Book Value Annual Sales$3.40 million Price / Sales11.43 Cash FlowN/A Price / Cash FlowN/A Book Value$0.15 per share Price / Book4.19Miscellaneous Outstanding Shares61,780,000Free Float50,471,000Market Cap$38.85 million OptionableOptionable Beta3.03 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. James R. McCullough M.B.A. (Age 56)Chief Executive Officer Comp: $1.04MMr. Thomas H. McLain CPA (Age 65)M.B.A, President Comp: $662.7kMr. Oliver James Sterling IIIChief Financial OfficerMr. Fergus Fleming (Age 56)Chief Technology Officer Dr. Michael J. Donovan M.D. (Age 69)Ph.D., Chief Medical Officer Mr. Howard B. Doran Jr. (Age 63)Chief Business Officer Mr. Salim Gulamabbas Hamir F.C.A.Company SecretaryMore ExecutivesKey CompetitorsInterlink ElectronicsNASDAQ:LINKLivePersonNASDAQ:LPSNTransAct TechnologiesNASDAQ:TACTInuvoNYSE:INUViCADNASDAQ:ICADView All CompetitorsInstitutional OwnershipPinnacle Associates Ltd.Sold 150,529 shares on 4/26/2024Ownership: 1.127%Simplex Trading LLCBought 400 shares on 2/2/2024Ownership: 0.000%View All Institutional Transactions RNLX Stock Analysis - Frequently Asked Questions Should I buy or sell Renalytix stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Renalytix in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RNLX shares. View RNLX analyst ratings or view top-rated stocks. What is Renalytix's stock price target for 2024? 1 Wall Street research analysts have issued 12 month target prices for Renalytix's shares. Their RNLX share price targets range from $5.00 to $5.00. On average, they predict the company's share price to reach $5.00 in the next twelve months. This suggests a possible upside of 695.2% from the stock's current price. View analysts price targets for RNLX or view top-rated stocks among Wall Street analysts. How have RNLX shares performed in 2024? Renalytix's stock was trading at $0.39 on January 1st, 2024. Since then, RNLX shares have increased by 61.2% and is now trading at $0.6288. View the best growth stocks for 2024 here. Are investors shorting Renalytix? Renalytix saw a decrease in short interest in the month of April. As of April 15th, there was short interest totaling 673,700 shares, a decrease of 15.3% from the March 31st total of 795,200 shares. Based on an average daily trading volume, of 1,830,000 shares, the days-to-cover ratio is presently 0.4 days. View Renalytix's Short Interest. When is Renalytix's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, June 14th 2024. View our RNLX earnings forecast. How were Renalytix's earnings last quarter? Renalytix Plc (NASDAQ:RNLX) posted its quarterly earnings data on Wednesday, February, 14th. The company reported ($0.09) EPS for the quarter, hitting the consensus estimate of ($0.09). The company earned $0.71 million during the quarter, compared to analysts' expectations of $0.70 million. Renalytix had a negative net margin of 1,736.47% and a negative trailing twelve-month return on equity of 1,008.88%. What other stocks do shareholders of Renalytix own? Based on aggregate information from My MarketBeat watchlists, some companies that other Renalytix investors own include Trevena (TRVN), Advanced Micro Devices (AMD), ChromaDex (CDXC), Chimerix (CMRX), CTI BioPharma (CTIC), DRDGOLD (DRD), Forte Biosciences (FBRX). When did Renalytix IPO? Renalytix (RNLX) raised $156 million in an initial public offering (IPO) on Friday, July 17th 2020. The company issued 11,000,000 shares at a price of $14.22 per share. J.P. Morgan and Stifel served as the underwriters for the IPO. Who are Renalytix's major shareholders? Renalytix's stock is owned by many different institutional and retail investors. Top institutional shareholders include Pinnacle Associates Ltd. (1.13%). How do I buy shares of Renalytix? Shares of RNLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:RNLX) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingThey say it’s ‘unstoppable’ – How I made 43,509% Investing DailyThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyProtect Your Bank Account Before It’s Too LateWeiss RatingsDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Renalytix Plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
